Related references
Note: Only part of the references are listed.Tumor Regression Grade in Gastric Cancer After Preoperative Therapy
Naruhiko Ikoma et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2021)
Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial
W. O. de Steur et al.
ANNALS OF ONCOLOGY (2021)
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
Ben M. Eyck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).
John V. Reynolds et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy
Sibo Tian et al.
CANCER (2020)
Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma
Syed Nabeel Zafar et al.
ANNALS OF THORACIC SURGERY (2020)
High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis
Xin Sun et al.
FRONTIERS IN ONCOLOGY (2020)
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET (2019)
Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy
Alexander P. Stark et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer
Dawei Chen et al.
JAMA ONCOLOGY (2019)
A hybrid automated treatment planning solution for esophageal cancer
Chifang Ling et al.
RADIATION ONCOLOGY (2019)
Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future
V. Aggelis et al.
ANNALS OF ONCOLOGY (2018)
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
Annemieke Cats et al.
LANCET ONCOLOGY (2018)
Dosimetric benefits of automation in the treatment of lower thoracic esophageal cancer: Is manual planning still an alternative option?
Xiadong Li et al.
MEDICAL DOSIMETRY (2017)
TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG
Trevor Leong et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction
Andrew R. Davies et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Small Bowel Dose Parameters Predicting Grade ≥3 Acute Toxicity in Rectal Cancer Patients Treated With Neoadjuvant Chemoradiation: An Independent Validation Study Comparing Peritoneal Space Versus Small Bowel Loop Contouring Techniques
Robyn Banerjee et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
P. van Hagen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
BIOGRAY – A TOOL FOR SIMULTANEOUS MODELLING TCP/NTCP; EVALUATION OF DVH AND QUANTEC DATA
P. Mattila et al.
RADIOTHERAPY AND ONCOLOGY (2011)
USE OF NORMAL TISSUE COMPLICATION PROBABILITY MODELS IN THE CLINIC
Lawrence B. Marks et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Share Paper
